cosibelimab-ipdl

AssetAlso called CK-301, TG-1501, Unloxcyt

Blocks PD-L1 to restore antitumor immune responses.

Stage
Approved
Modality
Antibody
Target
CD274
15
Indications
6
Trials
2
Developers

Approved by the FDA on Dec 13, 2024 (BLA761297). FDA

Indications

15
  • Metastatic cutaneous squamous cell carcinoma

    Approved, FDA

  • Locally advanced cutaneous squamous cell carcinoma

    Approved, FDA

  • Metastatic non squamous non small cell lung cancer

    Phase 3, Terminated, NCT04786964, clinicaltrials.gov, Nov 12, 2026

12 more

In the full profile

  • Target and mechanism2
  • Owner and partners2
  • Trials6
  • Evidence for its targets1
  • Competitors12
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets